Antagonists of RF-amide neuropeptides

Details Antagonists of RF-amide neuropeptides Antagonists of RF-amide neuropeptides

2005-11-01

2005-11-01

Raymond, Richard L. (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S001000, C514S019300, C514S601000, C514S613000, C514S631000, C514S649000, C540S553000, C540S604000, C540S609000, C206S570000

Reexamination Certificate

active

06960574

ABSTRACT:
Disclosed are compounds having the formula:whereR1=H, C1-C6alkyl, cycloalkyl,R2=H, C1-C6alkyl, cycloalkylW=CnH2n-m—NH (n=1-6, m=0, 2, or 4),X=R3=Y=Z=CONR8(CH2)n, CONR8(CH2)nCO, P(CH3)OCHR8OCOR9, SO2, SO2(CH2)n, SO2(CH2)nCO, SO2NR8(CH2)n, SO2NR8(CH2)nCO, n=1-4R4=H, (CH2)nOH, (CH2)nOCOR10, (CH2)nNR10R11, (CH2)nCONR10R11, n=0-4R5=H, (CH2)nNR12R13, n=0-4R6=H, (CH2)nNR14R15, n=0-4R7=H, C1-C6alkyl, cycloalkyl; R8=H, C1-C6alkyl, cycloalkyl; R9=H, C1-C6alkyl, cycloalkyl;R10=H, C1-C6alkyl, cycloalkyl; R11=H, C1-C6alkyl, cycloalkyl; R12=H, C1-C6alkyl, cycloalkyl;R13=H, C1-C6alkyl, cycloalkyl; R14=H, C1-C6alkyl, cycloalkyl; R15=H, C1-C6alkyl, cycloalkyl.Dashed lines: optional; conformational constraint by (CH2)n, n=1-3, R′=H or O(═) as well as pharmaceuticals compositions and methods for the treatment of opiate addiction, opiate dependence, opiate tolerance, opiate related abstinence syndrome, nicotine addition and obesity based thereon.

REFERENCES:
patent: 4988701 (1991-01-01), Olney
patent: 5011853 (1991-04-01), Olney
patent: 6323239 (2001-11-01), Dewey et al.
patent: 6541520 (2003-04-01), Dewey et al.
patent: 6562364 (2003-05-01), DiSanto et al.
patent: 6566400 (2003-05-01), Akunne et al.
patent: 6593367 (2003-07-01), Dewey et al.
patent: 2002006274 (2002-01-01), None
Lingford et al,PubMed Abstract 12697627, also cited as Br. Med. Bull., 65,209-22(2003.
Cador et al, PubMed 11958872, also cited as Neuroscience, 110/2,309-18(2002).
Malin et al, Puibmed Abstract 8804070, also cited as Peptides, 17/4,615-8(1996).
Kelley et al, PubMed Abstract 12117573, also cited as Physiolo. Behav., 76/3,365-77(2002).
Nystedt et al, PubMed 12354280, also cited as J. Neurochem., 82/6,1330-42(2002).
U.S. Appl. No. 10/109,00, filed Mar. 29, 2002.
Prokai et al, J. Med.Chem., 44/10.1623-26(2001).
Tan el al, Peptides (New York), 20/10, 1211-17(1999).
Tan et al,Peptides, 20, 1211-17(1999).
Prokai et al,J. Med. Chem. 44,1623-26(2001), also cited as Chemical Abstract DN 135 163.
Elshourbagy, et al., J. Biol. Chem. Chem. 2000, 275, 25965-25971.
Bonini, et al., J. Biol. Chem. 2000, 275, 39324-39331.
Yang et al., Proc. Natl. Acad. Sci., 1985, 82, 7757-61.
Yang et al., Prog. Clin. Biol. Res., 1985, 192, 313-22.
Panula et al., Med. Biology, 1987, 65, 127-35.
Kivipelto et al., Journal of Comparative Neurology.
Ferrarese et al., Regulatory Peptides, 1986, 13, 245-52.
Tang et al., Proc. Natl. Acad. Sci., 1984, 81, 5002-5.
Kavaliers et al., Peptides, 1989, 10, 741-5.
Kavaliers et al., Peptides, 1991, 12, 235-239.
Malin et al., Peptides, 1990, 11, 969-972.
Malin et al., Peptides, 1990, 11, 277-280.
Malin et al., Peptides, 1991, 12, 1011-4.
Malin et al., Drug Alcohol Depend. 1995, 40, 37-42.
Guzman et al., Neuropeptides 1989, 14, 253-261.
Majane et al., Peptides, 1987, 8, 657-662.
Majane et al., Peptides, 1988, 9, 1137-1144.
Majane et al., Peptides, 1990, 11, 969-972.
Allard et al., Brain Res., 1989, 500, 169-176.
Rothman, Synapse 1992, 12, 129-138.
Lake et al., Neurosci. Lett. 1991, 132, 29-32.
Payza, Peptides, 1987, 8, 1065-1074.
Tan et al., Peptides 1999, 20, 1211-1217.
Gicquel et al., J. Med. Chem. 1994, 37, 3477-3481.
Weiner et al., Comput. Chem. 1986, 7, 230-252.
Stewart, J. Comput. Chem. 1989, 10, 209-220.
Houghten et al., J. Med. Chem. 1999, 42, 3743-3778.
Furka et al., J. Pept. Protein Res. 1991, 37, 487-493.
Lipinski et al., Adv. Drug. Deliv. Rev. 1997, 23, 3-25.
Ghose et al., J. Comput. Chem. 1988, 9, 80-90.
Pidgeon et al., J. Med. Chem. 1995, 38, 590-594.
Reichel et al., Pharm. Res. 1998, 15, 1270-1274.
Lingford et al., PubMed Abstract 12697627, also cited as Br. Med. Bull., 65,209-22(2003).
Cador et al., PubMed 11958872, also cited as Neuroscience, 110/2,309-18(2002).
Malin et al., PubMed Abstract 8804070, also cited as Peptides, 17/4,615-8(1996).
Kelley et al., PubMed Abstract 12117573, also cited as Physiolo. Behav., 76/3,365-77(2002).
Nystedt et al., PubMed 12354280, also cited as J. Neurochem., 82/6, 1330-42(2002).
Tan et al., Peptides, 20, 1211-17 (1999).
Prokai et al., Rapid Commun. Mass Spectrom. 2000, 14, 2414-2418.
Prokai et al., J. Med. Chem. 44, 1623-26 (2001), also cited as Chemical Abstract DN 135:163.
A.M. Kawasaki et al., “Syntheses, opioid binding affinities, and potencies of dynorphin A analogues substituted in positions 1, 6, 7, 8 and 10”, International Journal of Peptide & Protein Research, 42, 1993, pp. 411-419.
Ambo et al., “ORLI receptor affinity & Biol. activity”, J. Tohoku Phar. Univ., 47, pp. 101-107 (2000), also cited as HCAPLUS DN 136:217029.
S.N. Kulkarni et al., “The use of the message-address concept in the design of potential antagonists based on dynorphin A”, Chem., Structure and Biol., Proceedings of Am. Peptide Symposium, 14th, Columbia, OH, Jun. 18-23, 1995/96, pp. 655-656.
B. Capuano et al., “Synthesis and preliminary pharmacological evaluation of 4′-arylmethyl analogues of clozapine”, Australian J. of Chemistry (2002). 55(9), pp. 565-576.
D. Proske et al., “A Y2 Receptor Mimetic Aptamer Director against Neuropeptide Y”, J. Biol. Chemistry, vol. 277, No. 13, Mar. 29, 2002, pp. 11416-11422.

Affiliated with

Also associated with

Rating

Antagonists of RF-amide neuropeptides does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antagonists of RF-amide neuropeptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antagonists of RF-amide neuropeptides will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3517889